Shanghai Labway Clinical Laboratory Co., Ltd. (301060.SZ)
CNY 8.9
(-0.45%)
CNY 8.9
(-0.45%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -135.82 Million CNY | -114.31% |
| 2022 | 949.27 Million CNY | 197.63% |
| 2021 | 318.94 Million CNY | 78.72% |
| 2020 | 178.46 Million CNY | 36.7% |
| 2019 | 130.55 Million CNY | 22.38% |
| 2018 | 106.67 Million CNY | 1394.27% |
| 2017 | 7.13 Million CNY | -92.11% |
| 2016 | 90.51 Million CNY | -22.36% |
| 2015 | 116.57 Million CNY | 32.67% |
| 2014 | 87.86 Million CNY | -20.75% |
| 2013 | 110.87 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 6.69 Million CNY | 146.03% |
| 2024 Q3 | -79.48 Million CNY | -1287.38% |
| 2024 Q1 | 2.72 Million CNY | 101.92% |
| 2023 Q2 | -28.67 Million CNY | -227.19% |
| 2023 Q3 | 11.8 Million CNY | 141.16% |
| 2023 FY | -135.82 Million CNY | -114.31% |
| 2023 Q4 | -141.49 Million CNY | -1298.92% |
| 2023 Q1 | 22.54 Million CNY | -60.13% |
| 2022 Q2 | 354.35 Million CNY | 26.68% |
| 2022 Q1 | 279.72 Million CNY | 481.21% |
| 2022 FY | 949.27 Million CNY | 197.63% |
| 2022 Q4 | 56.54 Million CNY | -78.14% |
| 2022 Q3 | 258.64 Million CNY | -27.01% |
| 2021 Q3 | 122.2 Million CNY | 72.23% |
| 2021 Q4 | 48.12 Million CNY | -60.62% |
| 2021 Q1 | 77.66 Million CNY | 157.89% |
| 2021 Q2 | 70.95 Million CNY | -8.65% |
| 2021 FY | 318.94 Million CNY | 78.72% |
| 2020 Q4 | 30.11 Million CNY | -55.36% |
| 2020 FY | 178.46 Million CNY | 36.7% |
| 2020 Q3 | 67.46 Million CNY | -4.02% |
| 2020 Q2 | 70.29 Million CNY | 563.77% |
| 2020 Q1 | 10.58 Million CNY | -55.04% |
| 2019 FY | 130.55 Million CNY | 22.38% |
| 2019 Q4 | 23.55 Million CNY | 0.0% |
| 2018 FY | 106.67 Million CNY | 1394.27% |
| 2017 Q1 | 31.96 Million CNY | 124.59% |
| 2017 Q2 | 31.96 Million CNY | 0.0% |
| 2017 FY | 7.13 Million CNY | -92.11% |
| 2016 Q3 | 14.23 Million CNY | -54.13% |
| 2016 Q4 | 14.23 Million CNY | 0.0% |
| 2016 FY | 90.51 Million CNY | -22.36% |
| 2016 Q1 | 31.02 Million CNY | -16.91% |
| 2016 Q2 | 31.02 Million CNY | 0.0% |
| 2015 FY | 116.57 Million CNY | 32.67% |
| 2015 Q1 | 20.94 Million CNY | 0.0% |
| 2015 Q3 | 37.33 Million CNY | 78.25% |
| 2015 Q4 | 37.33 Million CNY | 0.0% |
| 2015 Q2 | 20.94 Million CNY | 0.0% |
| 2014 FY | 87.86 Million CNY | -20.75% |
| 2013 FY | 110.87 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 998.13 Million CNY | 113.608% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.48 Billion CNY | 105.461% |
| Dirui Industrial Co.,Ltd. | 296.87 Million CNY | 145.751% |
| Beijing Strong Biotechnologies, Inc. | 593.87 Million CNY | 122.871% |
| Medicalsystem Biotechnology Co., Ltd. | 279.11 Million CNY | 148.662% |
| Maccura Biotechnology Co.Ltd | 331.14 Million CNY | 141.016% |
| Guangzhou Wondfo Biotech Co.,Ltd | 549.13 Million CNY | 124.734% |
| Guangdong Hybribio Biotech Co.,Ltd. | 42.59 Million CNY | 418.837% |
| BGI Genomics Co., Ltd. | 150.64 Million CNY | 190.159% |
| Amoy Diagnostics Co., Ltd. | 301.24 Million CNY | 145.087% |